Prospective mode of action of Ivermectin: SARS-CoV-2
European Journal of Medicinal Chemistry Reports, ISSN: 2772-4174, Vol: 4, Page: 100018
2022
- 13Citations
- 30Captures
- 2Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations13
- Citation Indexes13
- 13
- CrossRef2
- Captures30
- Readers30
- 30
- Mentions2
- News Mentions2
- 2
Most Recent News
Ivermectin: Could Population-Wide Distribution Have Prevented China's Recent Mass COVID Outbreak?
Authored by Dr. Sean Lin and Mingjia Jacky Guan via The Epoch Times (emphasis ours), China’s state-run medicare program recently failed to reach an agreement
Review Description
The well-known anti-helminthic drug ivermectin (IVM) has been established as an example of drug repurposing for the management of SARS-CoV-2 infection. Various study has been done to understand the inhibitory mechanism of IVM against SARS-CoV-2 targets. Broadly, IVM has been categorized as a host-directed agent and the proposed mechanism involves inhibition of the IMPα/ß1-mediated nuclear import of viral proteins. In addition, in vitro / in vivo and molecular docking/dynamic simulation studies suggested multitargets mechanism of IVM against SARS-CoV-2. Present manuscript attempts to provide an overview of the detailed mechanism of action based on experimental and computational studies. The knowledge of binding interaction of IVM and SARS-CoV-2 targets will give the direction to developed new and potential anti-COVID agents.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2772417421000182; http://dx.doi.org/10.1016/j.ejmcr.2021.100018; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85146131079&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/36593981; https://linkinghub.elsevier.com/retrieve/pii/S2772417421000182; https://dx.doi.org/10.1016/j.ejmcr.2021.100018
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know